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Abstract
Background: Despite certain contradictions, an association has been identified between adherence to
drug treatment and the quality of life in patients with type 2 diabetes. The contradictions observed
emphasize the importance of using different methods to measure treatment adherence, or the association
of psychological precursors of adherence with quality of life. For this reason, we have used an indirect
method to measure adherence (pill count), as well as two adherence behaviour precursors (attitude and
knowledge), to assess the association between adherence and the quality of life in type 2 diabetes patients.
Methods: A cross-sectional comparative study on a random sample of 238 type 2 diabetic patients was
carried out over one year in four family medicine units of the Mexican Institute of Social Security (IMSS)
in Aguascalientes, Mexico. Treatment adherence was measured using the indirect method of pill count to
assess adherence behaviour, obtaining information at two home visits. In the first we recorded the
medicine prescribed and in the second, we counted the medicine remaining to determine the proportion
of the medicine taken. We also assessed two adherence behaviour precursors: the patients' knowledge
regarding their medical prescription measured through a structured questionnaire; and attitudes to
treatment adherence using a Likert scale. Quality of life was measured through the WHOQOL-100 (the
WHO Quality of Life questionnaire). Information concerning both knowledge and attitude was obtained
through interviews with the patients. A multiple linear regression model was constructed to establish the
relationship between each quality of life domain and the variables related to adherence, controlling for
covariates.
Results: There was no association between quality of life and treatment adherence behaviour. However,
the combination of strong knowledge and a positive attitude was associated with five of the six quality of
life domains.
Conclusion: The results suggest that it is important to explore psychological precursors of treatment
adherence behaviour in type 2 diabetic patients. Indeed, we consider that it will be useful to carry out
interventions that change negative attitudes towards treatment adherence and that promote medical
prescription knowledge, which may help to improve the quality of life of such patients.
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Background
When patients with diabetes do not adhere to their drug
prescriptions the efficacy of the medication declines [1],
as does their control of glycaemia. Accordingly, there is a
higher risk of acute and chronic complications [2,3], lead-
ing to unnecessary hospital admissions [4]. A systematic
review of adherence to diabetes medication reported fre-
quencies between 36% to 93% [5]. Such variation was in
part associated with the method used to determine adher-
ence and indeed, while the adherence rate for patients tak-
ing sulfonylurea was 74.5% using electronic monitoring,
self-reported adherence was 92.4% [6].
It is clear that in terms of quality of life, chronically ill
individuals had lower mean quality of life domain scores
when compared to healthy adults or childbearing women
[7]. There are different results regarding the association
between quality of life and glycemic control, and while
some studies have clearly shown such an association [8-
10], this is not evident in other studies [11-14]. It has been
suggested that adherence to drug treatment and quality of
life are linked, although some contradictory results have
again appeared in different studies [15-19]. Some of these
discrepancies may reflect the limitations of the different
methods or instruments used to measure adherence.
Therefore, it seems to be important to measure treatment
adherence behaviour as well as its psychological precur-
sors.
The objective of this study was to assess the association
between quality of life and treatment adherence behav-
iour, medical prescription knowledge, attitude toward
treatment adherence, and a combination of knowledge
and attitude in type 2 diabetic patients.
Methods
Study design
A cross-sectional comparative study was carried out
between March 2003 and March 2004 in four Family
Medicine Units (FMU) of the Mexican Institute of Social
Security (IMSS) in Aguascalientes, Mexico.
Setting
In Mexico, the social security (IMSS) is the principal
health service provider and offering medical services to
more than 50% of the Mexican population. The IMSS also
maintains a Register of Chronic Degenerative Patients
(RPCD), a database that in 2001 had approximately
27,850 patients with diabetes in Aguascalientes. In this
city, the IMSS has six FMU, with a total of 86 medical
offices. Our study was carried out in 82.5% of the medical
offices.
Study population
Individuals that were included in this study were diag-
nosed with type 2 diabetes at least one year previously,
they were over 40 years of age and underwent treatment
with oral hypoglycemic agents. Patients with chronic
complications or disabling diseases, and patients on insu-
lin treatment were not included.
The sample size was calculated in order to identify a mean
difference in the quality of life of 10 points (on a scale of
0 to 100), with a mean of 70 in patients that adhered to
diabetes medication and a mean of 60 in those who did
not, as well as a standard deviation of ± 23, an alpha coef-
ficient of 0.05 and a power of 0.80. Accordingly, the sam-
ple size required was calculated to be 84 patients per
group. This study was approved by the scientific and ethi-
cal review Committee N° 101 of the IMSS with reference
number 2002/01/02/04 and written informed consent
was obtained from all patients as they were recruited at
the health care units. Subjects were randomly selected
from the RPCD.
Study variables
The dependent variable was the quality of life score, the
independent variables were the Treatment Adherence
Behaviour, Medical Prescription Knowledge, Attitude
toward Treatment Adherence, and a combination of
Knowledge and Attitude. Age, gender, educational level,
marital status, hypertension, hypoglycaemic prescription,
diabetes duration, fasting glucose, and HbA1c were used
as control variables.
The Health Related Quality of Life (HRQOL) scale was
defined as the individuals' perception of their situation in
the context of the culture and value systems in which they
live, and in relation to their goals, expectations, standards
and concerns. This is a broad concept affected in a com-
plex way by the individuals physical health, psychological
state, level of independence, social relationships, personal
beliefs and their relationship to salient features of their
environment [20].
In 2001, the WHO organized a meeting to deal with the
issue of "adherence". From the definitions of Haynes [21]
and Rand [22], they adopted the definition of "adherence
to long-term therapy" as: the extent to which a person's
behaviour in taking medication, following a diet and/or
executing lifestyle changes, corresponds with the agreed
recommendations of a health care provider [23]. It is
known that in order to achieve satisfactory adherence
patients must possess adequate knowledge about self-care
behaviour [24], and that attitudes play an important role
in changing adherence behaviour, since they predict and
explain human behaviour [25]. Therefore, we decided toBMC Health Services Research 2008, 8:164 http://www.biomedcentral.com/1472-6963/8/164
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measure Medical Prescription Knowledge and Attitude
toward Treatment Adherence as adherence precursors.
Data collection
Three healthcare professionals were trained to interview
patients so that the same questions were asked in the same
way, and unusual circumstances were handled similarly.
Patients were invited to participate when they had an
appointment with their family physician, and the inter-
viewers then arranged a home visit in order to complete a
questionnaire regarding certain personal characteristics,
as well as to count and register the oral hypoglycemic
agents. The next day, we reviewed the medical records of
each patient and noted their medical prescription. One
month later, the interviewers again visited the patients to
register the pill count (measure of treatment adherence
behaviour), and to ask about their quality of life, knowl-
edge of their medical prescription and their attitude to
treatment adherence. The patients were requested to
attend the laboratory the next day to examine their glu-
cose levels (fasting glucose and HbA1c).
Treatment Adherence Behaviour (behaviour) was consid-
ered a discrete variable and it was analyzed by grouping
patients according to the classification proposed by
Mason, Matsuyama and Jue [6]. Accordingly, patients
were classified with a good behaviour when 90% to 105%
of the prescribed medication was taken, whereas patients
that took <90% or >105% were classified with a poor
behaviour. The percentage adherence was calculated by
dividing the difference in the number of pills in the first
home visit and the pills remaining at the second home
visit by the number of pills prescribed for the interval, and
multiplying the result by 100 [6].
Medical Prescription Knowledge (knowledge) was consid-
ered a discrete variable, which was measured with the
knowledge questionnaire that addressed three issues: the
name of the oral hypoglycaemic agents; the dosage; and
the dosage frequency. Patients were classified with strong
knowledge if their answers agreed with the medical pre-
scription. When at least one response did not agree with
the medical prescription we classified these patients with
weak knowledge.
Attitude to Treatment Adherence (attitude) was consid-
ered a discrete variable and the attitude questionnaire
addressed six domains with eleven items. Domains were
identified by experts in a thorough search for information
about the causes of non-adherence: wellbeing/discomfort
(AQ1, AQ2); belief about damage caused by medication
(AQ3); the diabetes-treatment complications relationship
(AQ4, AQ5); barriers/facilitators to taking medication
(AQ6, AQ7); accessibility to healthcare and medical treat-
ment (AQ8, AQ9); and doctor-patient agreements about
treatment (AQ10, AQ11). Experts developed eleven ques-
tions, two of which were reworded from the Morisky scale
[26]. The items were rated on a 5-point Likert scale: 5 =
strongly agree, 4 = agree, 3 = indifferent, 2 = disagree, 1 =
strongly disagree. The scale was scored by summing the
patients' responses and dividing this score by the number
of items. If the result was 4 or 5 we classified the patients
with a positive attitude, whereas a result between 1 and 3
was classified with negative attitude.
A group of experts used a consensus panel process to gen-
erate the items and validate the content. The experts
agreed that the content of both questionnaires was valid.
The face validity was measured through the identification
of ambiguous items by a group of diabetic patients, and
minor changes in wording were made based on their com-
ments.
The attitude questionnaire structure was confirmed
through a principal component analysis which yielded
the same six factors identified by the experts, the eigenval-
ues were >1 and explained 77.5% of the variance. This
analysis supported the construct validity. Moreover, this
questionnaire had an acceptable internal consistence
(Cronbach's alpha = 0.74).
When the performance of the attitude and knowledge
questionnaires was evaluated independently, both ques-
tionnaires showed low values of specificity and negative
predictive value. These values should be higher in a pop-
ulation with high non-adherence prevalence [27], as in
this study.
The attitude and knowledge questionnaires were com-
bined in order to improve their performance through a
serial analysis [28]. This analysis considered a patient with
positive attitude and strong knowledge as adherent, and a
patient with negative attitude or weak knowledge was
classified as non-adherent.
The criterion validity was assessed through a performance
analysis of the questionnaires, both independently and in
a combined manner, taking the pill count (behaviour) as
the gold standard. The combination of questionnaires
showed the best performance with a specificity of 77.4 %
and a negative predictive value of 77.9 %, it identified
most of the non-adherent patients.
The questionnaires are shown as an additional file [see
Additional file 1], the English version is a translation of
the original Spanish questionnaires (available from the
first author) that has not been adapted to this language.
Quality of life was assessed by means of the World Health
Organization Quality of Life 100 item questionnaireBMC Health Services Research 2008, 8:164 http://www.biomedcentral.com/1472-6963/8/164
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(WHOQOL-100). This was developed by the World
Health Organization (WHO) [14] and it consists of six
domains: physical, psychological, level of independence,
social relationships, environment and spirituality. These
domains contain 24 facets, each of which includes four
items leading to a total of 96 items. One additional facet
of four items pertains to the global quality of life and gen-
eral health. This facet is not included in the WHOQOL-
100 domain structure but it is analyzed as part of the
instrument. Each of the facets is summed and each item
contributes equally to the facet score and the domain
score. All facet scores and domain scores in the WHO-
QOL-100 are transformed to reflect a scale from 0 to 100,
with higher scores reflecting a higher quality of life
[29,30]. The original English-language version was trans-
lated into Spanish using a method developed by the WHO
that included forward and back translation, a bilingual
panel of experts and a monolingual panel of diabetics in
focus groups. Reliability was assessed by calculating the
Cronbach α coefficient (of internal consistency), which
was similar to that in other studies and within a range of
0.71 to 0.90 [31].
Statistical analysis
Descriptive statistics were calculated for the sociodemo-
graphic and clinical characteristics of type 2 diabetic
patients, for behaviour, and for the combination of
knowledge and attitude. Continuous data with a normal
distribution were described by the mean and standard
deviation, and for data that did not have a normal distri-
bution the median and quartiles were used.
An unpaired Student's t test was used to compare the
means of each quality of life domain between binary var-
iables, an analysis of variance (ANOVA) was used as a par-
ametric test of significance for categorical variables, and
the Mann-Whitney U was used as non-parametric test of
significance when medians had to be compared. Correla-
tions between each quality of life domain and the varia-
bles with continuous data were tested with Pearson's r
coefficient, when a linear relationship could be confirmed
with a scatter plot, otherwise Spearman's rho was used. All
results were judged to be statistically significant at the 5 %
level (p < 0.05).
A backward multiple linear regression model was con-
structed to establish the relationship between each quality
of life domain and the variables related to adherence, con-
trolling for covariates. For each quality of life domain the
initial model included all the variables that were found to
be significantly related in the univariate analysis. Varia-
bles entered the model with an α ≤ 0.05, and they were
removed with an α > 0.10. An adjusted R2 was estimated
for the final models to determine the amount of variance
in each domain of the quality of life score explained by
the predictor variables. Data processing and regression
diagnostics used to assess the model assumptions were
carried with the STATA statistical software version 9.0
[32].
Results
When the sociodemographic and clinical characteristics of
the patients were analysed, we identified a slightly higher
proportion of females in the study (Table 1). The subjects
were mostly literate with a basic education level, they were
predominantly married and their mean age was 58.7
years. Most of them had hypertension, and they had been
prescribed two or three oral hypoglycaemic agents.
Patients had a median duration of diabetes of 6 years, and
their median fasting glucose was 8.8 mmol/L and the
mean HbA1c was 8.8 %.
Only 17.2% of patients showed good treatment adher-
ence behaviour, similar to the results regarding to the pre-
cursors of adherence, the combination of knowledge and
attitude, where 20.6% of patients displayed both strong
knowledge and positive attitude.
The mean scores for each domain of the quality of life
scale ranged from 63.1 in the independence domain to
73.9 in the spirituality domain.
The mean quality of life score was significantly higher for
male patients than females in the physical, psychological
and the environment domain (p < 0.05), but there were
no significant differences in the level of independence,
social relationship and spirituality domain. With the
exception of spirituality, the rest of the domains showed
significant differences (p < 0.05) in all categories of edu-
cational level, and the mean score in each quality of life
domain increased as the educational level also rose. More-
over, patients without hypertension only showed signifi-
cantly higher scores in the level of the independence
domain (p < 0.05). However, there were no significant
differences between the mean quality of life scores in any
of the six domains between patients with monotherapy
and patients receiving more than one oral hypoglycaemic
agent (Table 2). There was a significant correlation (p <
0.05) between the level of independence domain and age,
as well as with the duration of diabetes. Similarly, the psy-
chological and the environment domain were signifi-
cantly correlated with the fasting glucose levels (p < 0.05,
Table 3).
There were no significant differences between the mean
scores in any of the six quality of life domains and the
patients' behaviour toward treatment adherence. How-
ever, when there was a combination of strong knowledge
and a positive attitude, a significant difference was
observed in the mean scores of all the domains (Table 4).BMC Health Services Research 2008, 8:164 http://www.biomedcentral.com/1472-6963/8/164
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A multiple linear regression analysis is presented for each
of the quality of life domains (Table 5) and it was evident
that none of the study variables were associated with the
spirituality domain. Patients with a higher education level
and a combination of strong knowledge and positive atti-
tude had an increased probability of higher scores in the
physical domain, explaining 8% of the variability in the
patients' scores. Male patients, with a higher educational
level, and a combination of strong knowledge and posi-
tive attitude, had a higher probability of achieving greater
scores in the psychological domain. This model explained
18 % of the variability in the scores. Patients with a higher
level of education, without hypertension, and with a com-
bination of strong knowledge and positive attitude had a
greater probability of achieving higher scores at the level
of the independence domain, but this probability dimin-
ished as the duration of diabetes increased. This model
explained 9 % of the variability in the scores. Patients with
a higher educational level and a combination of strong
knowledge and positive attitude had an increased proba-
bility of higher scores in social relationship domain. This
model explained 8 % of the variability in the scores.
Finally, older male patients with a higher level of educa-
tion, and a combination of strong knowledge and positive
attitude, had a greater probability of achieving higher
scores in the environment domain. However, this proba-
bility diminished as the glucose levels increased. This
model explained 14 % of the variability in the scores.
Discussion
In this study, treatment adherence behaviour was not
associated with any quality of life domain. However, an
association was observed when we combined two precur-
sors of adherence, medical prescription knowledge and
attitude to treatment adherence, with five of the six
domains (physical, psychological, level of independence,
social relationship and environmental).
In contrast to previous studies carried out on a Mexican
population with type 2 diabetes where 50% of patients
were adherent to their treatment [33,34], only 17.2 % of
the patients displayed good adherence behaviour here as
Table 1: Characteristics of diabetic type 2 patients (n = 238).
CHARACTERISTICS
Sociodemographic characteristics
Gender n (%)
Female 148 (62.2)
Male 90 (37.8)
Educational level n (%)
No education 20 (8.4)
Basic education 169 (71.0)
Intermediate level 24 (10.1)
Higher education 25 (10.5)
Marital status n (%)
Singled 13 (5.5)
Married/Free union 182 (76.5)
Divorced/Widow (er) 43 (18.1)
Age mean (SD) 58.7 (9.6)
Clinical characteristics
Hypertension n (%)
Yes 150 (63.0)
No 88 (37.0)
Hypoglycaemic prescription n (%)
Monotherapy 81 (34.0)
Polytherapy 157 (66.0)
Duration of diabetes in years
(since first diagnosis) median (quartiles) 6 (3–12)
Fasting Glucose mmol/L median (quartiles) 8.8 (6.9–11.9)
HbA1c % mean (SD) 8.8 (2.3)
Adherence
Treatment Adherence Behaviour n (%)
Good 41 (17.2)
Poor 197 (82.8)
Combination of knowledge and attitude n (%)
Good 49 (20.6)
Poor 189 (79.4)BMC Health Services Research 2008, 8:164 http://www.biomedcentral.com/1472-6963/8/164
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measured through a pill count. The earlier studies classi-
fied patients as adherent if they took ≥ 80% of the medi-
cine prescribed, although this classification method may
introduce a bias due to misclassification as indicated by
Pullar T [35]. We used a narrower classification scale of
90% to 105% in order to reduce this problem, as sug-
gested by Mason, Matsuyama and Jue [6]. Pill count in
this study showed a sensitivity to adherence of 83.3% and
a specificity of 89.4%, using electronic monitoring as the
gold standard [36]. Co-morbidity may be an important
characteristic that could modify adherence behaviour [37-
39], and it is common that diabetic patients also suffer
hypertension. Indeed, in our study population 63% of the
patients suffered hypertension.
Table 3: Correlation coefficients between sociodemographic and clinical characteristics of diabetic type 2 patients with quality of life 
domains.
SOCIODEMOGRAPHIC 
AND CLINICAL 
CHARACTERISTICS
QUALITY OF LIFE
Physical Psychological Level of 
independence
Social 
relationships
Environment Spirituality/Religion/
Personal beliefs
Age* -0.01 0.04 -0.17† -0.03 0.10 0.03
Duration of diabetes in 
years (since first 
diagnosis)**
-0.02 0.09 -0.17† -0.02 0.09 0.07
Fasting Glucose mmol/L** -0.08 -0.15† -0.00 -0.09 -0.18† -0.00
HbA1c %* -0.05 -0.05 -0.00 -0.00 -0.11 0.00
†P < 0.05
* Pearson's r
** Spearman's rho
Table 2: Means of the quality of life scores between sociodemographic and clinical characteristics of diabetic type 2 patients.
SOCIODEMOGRAPHIC 
AND CLINICAL 
CHARACTERISTICS
QUALITY OF LIFE
Physical Psychological Level of 
independence
Social 
relationships
Environment Spirituality/
Religion/Personal 
beliefs
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Gender
Female 62.4 (17.5)† 64.5 (14.6)† 62.7 (13.7) 70.0 (12.6) 65.6 (10.6)† 74.2 (16.9)
Male 67.2 (16.6)† 73.1 (10.1)† 63.8 (13.4) 72.3 (9.8) 69.6 (8.8)† 73.5 (17.3)
Educational level
No education 59.6 (21.3)† 61.4 (17.2)† 58.9 (16.6)† 65.0 (12.9)† 61.0 (11.7)† 71.8 (19.9)
Basic education 62.5 (16.4)† 66.5 (13.0)† 61.9 (12.6)† 69.8 (11.1)† 66.6 (9.7)† 74.3 (15.5)
Intermediate level 69.6 (18.0)† 73.6 (12.8)† 67.9 (15.5)† 76.8 (9.8)† 69.6 (9.8)† 74.2 (24.1)
Higher education 74.1 (14.9)† 76.0 (11.8)† 70.5 (12.1)† 77.0 (11.7)† 73.5 (8.7)† 73.2 (17.3)
Marital status
Singled 55.7 (17.0) 61.7 (13.6) 59.8 (12.6) 68.0 (14.0) 66.2 (12.9) 74.0 (18.8)
Married/Free union 64.7 (17.2) 68.1 (13.9) 63.4 (13.6) 71.2 (11.6) 67.2 (10.1) 73.6 (17.5)
Divorced/Widow(er) 64.7 (17.5) 68.1 (13.0) 63.3 (13.7) 70.3 (11.2) 67.0 (9.7) 75.2 (14.4)
Hypertension
Yes 63.6 (16.6) 66.7 (13.7) 61.9 (14.3)† 70.3 (11.7) 67.3 (10.8) 73.8 (17.1)
No 65.2 (18.5) 69.6 (13.6) 65.3 (12.0)† 71.9 (11.5) 66.9 (9.0) 74.2 (17.0)
Hypoglycaemic 
prescription
Monotherapy 64.7 (16.5) 68.6 (13.9) 63.8 (14.2) 70.8 (12.1) 66.9 (10.7) 73.6 (19.7)
Polytherapy 63.9 (17.7) 67.3 (13.6) 62.8 (13.3) 70.9 (11.4) 67.3 (9.8) 74.1 (15.5)
†P < 0.05BMC Health Services Research 2008, 8:164 http://www.biomedcentral.com/1472-6963/8/164
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Since the criterion validity for the combination of knowl-
edge and attitude was good, we used them as precursors of
adherence behaviour. Indeed, they are both easy to apply
and cheap, and thus, they can be readily used in daily
practice within a public primary health care setting where
there are always budget constraints. Both the attitude scale
and the knowledge questionnaire showed low sensitivity
and specificity, which means that it is not advisable to use
them in isolation but rather, they should be used together
to obtain valid information regarding patient adherence
precursors. We do not have information of studies that
have evaluated medical prescription knowledge and atti-
tude toward treatment adherence as adherence precursors,
and therefore, we can not make any comparison.
The mean quality of life scores for the different domains
ranged from 63.1 to 73.9. We selected patients without
diabetic complications and therefore, the quality of life
may be overestimated since such complications have an
important impact on patient's quality of life. In fact, our
study population displayed higher scores in all of the
quality of life domains when compared with Bonomi's
chronic patients [7] and Lingjiang's hypertensive patients
[30]. When our patients were compared with a healthy
population [7], they were attributed lower scores in
almost all domains, except the social relationships and
spirituality domains. Religion is by nature social and Mex-
ican culture has a strong religious burden [40]. Hence, we
can explain the higher scores in these domains (social
relationships, spirituality) since 96.5% of Mexicans pro-
fess some religion and 92% of them are Catholics [41].
Spiritual well being has been suggested as an important
internal source that people use to adjust to the problems
that a disease such as diabetes may generate [42].
In diabetic patients, quality of life is affected when there
are co-morbid conditions [43] or complications [44], and
in relation to their treatment, the use of insulin is nega-
tively associated with their quality of life [45]. The associ-
ation between adherence to oral hypoglycaemic agents
and quality of life has been evaluated using different
methods to measure adherence. While Cote [19] and
Holzemer [17] used self-reporting, Billups [18] and Sung
[16] used computerized prescription records. As in our
study, none of these studies found an association between
adherence and any quality of life domain. Other demo-
graphic and psychosocial factors have been associated
with quality of life, such as associations between personal
attitude of patients and solid specific knowledge of diabe-
tes. Thus, patients with a good, optimistic outlook on life
and strong beliefs in self efficacy had a better quality of life
score [46]. Indeed, another study found that satisfaction
in social relationships and friendships, worry about dia-
betic complications and treatment satisfaction contributes
to the strongest variation in patient's quality of life [47].
In these studies, analyses within specific quality of life
domains were made.
Educational level was the only sociodemographic variable
associated with five of the six quality of life domains.
Although there are contradictory results about this rela-
tionship, diabetic patients with higher education may
have better social support, positive self esteem, a better
understanding of the disease, its treatment and complica-
tions [47,48], characteristics that may promote strong
knowledge and positive attitude about treatment adher-
ence.
The level of education and the combination of knowledge
and attitude were weakly associated with the physical,
Table 4: Means in quality of life scores between adherence and its precursors.
ADHERENCE 
AND ITS 
PRECURSORS
QUALITY OF LIFE
Physical Psychological Level of 
independence
Social relationships Environment Spirituality/
Religion/Personal 
beliefs
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Treatment 
Adherence 
Behaviour
Good 67.5 (16.3) 70.4 (14.9) 64.4 (14.7) 73.0 (11.7) 69.4 (11.2) 74.8 (20.5)
Poor 63.5 (17.4) 67.2 (13.4) 62.9 (13.3) 70.4 (11.6) 66.7 (9.8) 73.8 (16.3)
Combination of 
knowledge and 
attitude
Good 71.5 (15.7)† 74.3 (11.3)† 66.8 (12.5)† 74.9 (9.5)† 71.7 (8.1)† 78.6 (17.3)†
Poor 62.3 (17.2)† 66.1 (13.8)† 62.2 (13.7)† 69.8 (11.9)† 66.0 (10.3)† 72.7 (16.8)†
†P < 0.05BMC Health Services Research 2008, 8:164 http://www.biomedcentral.com/1472-6963/8/164
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level of independence and social relationship domains.
This association may be explained by the absence of other
determinants of the quality of life in the model, such as
complications or other psychological variables. Neverthe-
less these two variables had a stronger association in the
psychological and environmental domains, probably due
to the fact that these domains take into account the per-
ceptions such as positive experiences, ability to make deci-
sions, and the way patients feel themselves, as well as the
patients sense of freedom, security of having financial
resources to meet their needs, and the opportunity to
acquire new skills and knowledge.
The association between most of the quality of life
domains with the combination of knowledge and attitude
to treatment adherence abides by the congruity principle
of Osgood and Tannenbaum [49]. This can be explained
by the "associative assertions" that patients show when
they give a positive evaluation in both quality of life (high
mean scores) and strong knowledge and positive attitude
to treatment adherence, as well as the negative evaluation
when the lowest mean scores in terms of weak knowledge
and negative attitude toward treatment adherence. Thus,
strong knowledge and positive attitude as precursors of
good adherence behaviour may promote and improve the
quality of life. This explanation is consistent with the
model proposed by Rose M et al. [46].
Limitations
This study had some limitations, such as the fact that the
cross-sectional study design ascertained quality of life and
adherence at the same time. Although, there was an asso-
ciation between these variables, we do not know its direc-
tionality, that is, we do not know if higher scores in
quality of life could have caused adherence or if non-
adherence could have caused lower scores in quality of
life. Besides, since these variables are continuums and
they change over time, measurements at only one point in
time as taken here have more limited value. Therefore, a
longitudinal study would provide a more complete pic-
ture regarding which of these variables could predict the
other, controlling for exposure changes. Since participants
were enrolled in primary care and lived in a city, the
results can not be easily transferred to all diabetic patients.
Furthermore, some authors have mentioned that home
visits may influence medication-taking [6] causing an
overestimation of the results. Nevertheless, we realized
that it was important to visit patients because most of
them had more medications at home than the ones they
received in their last medical consultation. Thus, in this
way we were able to register all their tablets. Moreover,
adherence magnitude in this study was lower than other
studies that have used a different measurement method
[37]. Finally, complications or insulin prescription are
known confounders, since these variables are associated
with an impairment in quality of life [44,45] and with
lower adherence [37,50]. An accepted strategy to control
confounders is restriction and therefore, we did not
include patients with complications or those that were
prescribed insulin.
Conclusion
In this study, we identified an association between most
quality of life domains and the combination of medical
prescription knowledge and attitude toward treatment
adherence in type 2 diabetic patients. Based on these
results, we consider it important to explore psychological
precursors of treatment adherence behaviour in type 2
diabetic patients and to carry out interventions that
change negative attitude toward treatment adherence and
promote medical prescription knowledge, which may
help to improve the quality of life of such patients.
Table 5: Multiple lineal regression analysis of predicting variables for quality of life.
SOCIODEMOGRAPHIC 
AND CLINICAL 
CHARACTERISTICS 
AND ADHERENCE 
PRECURSORS
QUALITY OF LIFE
Physical Psychological Level of 
independence
Social relationships Environment Spirituality/Religion
/Personal beliefs
β * P-value β P-value β P-value β P-value β P-value β P-value
Gender 0.26 0.00 0.15 0.01
Educational level 0.21 0.00 0.23 0.00 0.21 0.00 0.25 0.00 0.23 0.00
Age 0.17 0.00
Hypertension 0.11 0.05
Duration of diabetes in 
years (since first 
diagnosis)
-0.15 0.01
Fasting Glucose mmol/L -0.13 0.03
Combination of 
knowledge and attitude
0.19 0.00 0.16 0.00 0.11 0.05 0.14 0.02 0.16 0.00
R2 = 0.09 R2a = 0.08 R2 = 0.20 R2a = 0.18 R2 = 0.10 R2a = 0.09 R2 = 0.09 R2a = 0.08 R2 = 0.15 R2a = 0.14
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